Evolus (NASDAQ:EOLS) Insider Sells $14,815.25 in Stock

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 3,119 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $4.75, for a total transaction of $14,815.25. Following the transaction, the insider directly owned 427,423 shares in the company, valued at $2,030,259.25. This represents a 0.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Rui Avelar also recently made the following trade(s):

• On Tuesday, March 17th, Rui Avelar sold 29,996 shares of Evolus stock. The shares were sold at an average price of $4.89, for a total transaction of $146,680.44.
• On Monday, December 22nd, Rui Avelar sold 2,261 shares of Evolus stock. The shares were sold at an average price of $7.15, for a total value of $16,166.15.

Evolus Price Performance

Shares of NASDAQ:EOLS opened at $4.64 on Monday. The company has a market capitalization of $301.88 million, a P/E ratio of -5.73 and a beta of 1.02. Evolus, Inc. has a 1 year low of $4.09 and a 1 year high of $13.30. The business’s 50 day simple moving average is $4.79 and its 200 day simple moving average is $6.03.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.09). The business had revenue of $90.30 million during the quarter, compared to analysts’ expectations of $89.58 million. On average, sell-side analysts anticipate that Evolus, Inc. will post -0.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Evolus

Institutional investors have recently modified their holdings of the business. Manchester Capital Management LLC bought a new stake in shares of Evolus during the 2nd quarter worth $26,000. State of Alaska Department of Revenue bought a new position in Evolus in the third quarter valued at about $26,000. Larson Financial Group LLC raised its stake in Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after acquiring an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Evolus in the fourth quarter worth about $34,000. Finally, Wexford Capital LP bought a new position in shares of Evolus in the third quarter worth about $37,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Stifel Nicolaus reduced their price objective on shares of Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. BTIG Research reissued a “buy” rating and issued a $13.00 target price on shares of Evolus in a report on Wednesday, March 4th. HC Wainwright dropped their target price on shares of Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Evolus has a consensus rating of “Moderate Buy” and an average price target of $16.00.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.